<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="158166">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02022293</url>
  </required_header>
  <id_info>
    <org_study_id>2013018</org_study_id>
    <secondary_id>SYSN003</secondary_id>
    <nct_id>NCT02022293</nct_id>
  </id_info>
  <brief_title>Atorvastatin in Preventing Nasopharyngeal Carcinoma Patients Receiving Radiotherapy From Carotid Stenosis</brief_title>
  <official_title>Atorvastatin in Preventing Nasopharyngeal Carcinoma Patients Receiving Radiotherapy From Carotid Stenosis: A Multicenter, Double-blind, Placebo-Controlled, Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University</source>
  <oversight_info>
    <authority>China: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with head and neck cancer who underwent irradiation have a higher risk of
      developing severe carotid stenosis, and eventually develop to transient ischemic attack or
      stroke. However, it's still not clear whether early intervene in vascular risk factors is
      benefit for patients after radiotherapy.

      Our study aimed to evaluate the feasibility and safety of atorvastatin for preventing NPC
      patients after radiotherapy from severe carotid stenosis. In a randomized, double-blind,
      placebo-controlled trial, about 324 nasopharyngeal carcinoma (NPC) patients will be enrolled
      from six centers in Guangdong Province and randomized 1:1 to atorvastatin group or placebo
      group.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It is a randomized, double-blind, placebo-controlled trial, about 324 nasopharyngeal
      carcinoma (NPC) patients will be enrolled from six centers in Guangdong Province and
      randomized 1:1 to atorvastatin group (20mg per night, totally 2 years) or placebo group. All
      Patients will be followed up for 2 years. Ultrasound and Transcranial Color Doppler (TCD)
      will be used to evaluate the changes of intima-media thickness (IMT) and occurrence of
      plaque formation of carotid arteries. Safety will be monitored every 6 months.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">January 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Change from baseline in maximal of IMT of bilateral carotid arteries</measure>
    <time_frame>At baseline and 2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Patients will take Ultrasound and Transcranial Color Doppler every 6 months to measure the thickness of intima-media thickness (IMT) and occurrence of plaque formation of carotid arteries. We will compare the maximal IMT of bilateral carotid arteries at 2 years from baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of sever carotid stenosis</measure>
    <time_frame>At 2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Patients will be followed up for 2 years. We defined sever carotid stenosis as stenosis&gt;50% by using ultrasound and TCD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of cardiovascular events</measure>
    <time_frame>At 2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Patients will be followed up for 2 years and cardiovascular events such as stroke, transient ischemic attack (TIA) will be recorded.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">324</enrollment>
  <condition>Nasopharyngeal Carcinoma</condition>
  <condition>Radiation Therapy Complication</condition>
  <arm_group>
    <arm_group_label>Atorvastatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will take atorvastatin 20mg per night, totally 2 years.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will take placebo once per night for 2 years. The appearance and dosage of placebo will be the same as atorvastatin.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
    <description>Patients in this group will take 20mg per night.</description>
    <arm_group_label>Atorvastatin</arm_group_label>
    <other_name>Atorvastatin Calcium Tablets</other_name>
    <other_name>Lipitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must have received radiation therapy for histologically confirmed
             nasopharyngeal carcinoma.

          -  Prior irradiation &lt;3 years prior to study entry.

          -  Male or fertile women who are willing to take contraception during the trial.

          -  Age 40-65 years old.

          -  Carotid stenosis &lt; 50%.

          -  LDL-C between 100mg/dL（2.5mmol/L）and 190mg/dL（4.9mmol/L）.

          -  Ability to understand and the willingness to sign a written informed consent
             document.

        Exclusion Criteria:

          -  History of bleeding related to tumor or radiotherapy during or after radiation.

          -  Evidence of tumor invasion to major vessels(for example the carotid artery).

          -  Severe complications, such as history of stroke, myocardial infarction, liver
             diseases, thyroid dysfunction, inadequately controlled hypertension and epilepsy.

          -  Familial hypercholesterolemia.

          -  Taking lipid-lowing drugs.

          -  Aspartate aminotransferase(AST) or alanine aminotransferase(ALT) &gt;upper limits of
             normal (ULN), creatinine &gt;ULN.

          -  Allergic history of atorvastatin.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ying Peng, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen Memorial Hospital, Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ying Peng, Ph.D</last_name>
    <phone>+8613380051581</phone>
    <email>2353352460@qq.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yamei Tang, Ph.D</last_name>
    <phone>+8613556001992</phone>
    <email>yameitang@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Dongguan People's Hospital</name>
      <address>
        <city>Dongguan</city>
        <state>Guangdong</state>
        <zip>523059</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Weimin Xiao, Ph.D</last_name>
    </contact>
    <investigator>
      <last_name>Weimin Xiao, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510120</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ying Peng, Ph.D</last_name>
      <phone>+8613380051581</phone>
      <email>2353352460@qq.com</email>
    </contact>
    <contact_backup>
      <last_name>Yamei Tang, Ph.D</last_name>
      <phone>+8613556001992</phone>
      <email>yameitang@hotmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Ying Peng, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ying Sun, Ph.D</last_name>
      <phone>+8613688856258</phone>
      <email>sunying2@mail.sysu.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Ying Sun, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zengcheng People's Hospital</name>
      <address>
        <city>Zengcheng</city>
        <state>Guangdong</state>
        <zip>511300</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qingyu Shen, Ph.D</last_name>
      <phone>+8613609710406</phone>
      <email>super-shen@126.com</email>
    </contact>
    <investigator>
      <last_name>Qingyu Shen, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Affiliated Hospital of Guangdong Medical College</name>
      <address>
        <city>Zhanjiang</city>
        <state>Guangdong</state>
        <zip>524001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bin Zhao, Ph.D</last_name>
      <email>zhaobime@163.net</email>
    </contact>
    <investigator>
      <last_name>Bin Zhao, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Guangxi Medical University</name>
      <address>
        <city>Nanning</city>
        <state>Guangxi</state>
        <zip>530021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chao Qin, Ph.D</last_name>
      <email>mdqc6639@126.com</email>
    </contact>
    <investigator>
      <last_name>Chao Qin, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 7, 2014</lastchanged_date>
  <firstreceived_date>December 11, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University</investigator_affiliation>
    <investigator_full_name>Yamei Tang</investigator_full_name>
    <investigator_title>Professer</investigator_title>
  </responsible_party>
  <keyword>Nasopharyngeal Carcinoma</keyword>
  <keyword>Radiotherapy</keyword>
  <keyword>Carotid Stenosis</keyword>
  <keyword>Atorvastatin</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carotid Stenosis</mesh_term>
    <mesh_term>Constriction, Pathologic</mesh_term>
    <mesh_term>Nasopharyngeal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Atorvastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
